Our Story

Innovation ability was fully recognized in this phase when it was approved by the government as a high-tech enterprise in Shenzhen in 2005, and awarded the "Champion of the First Innovation Nanshan Entrepreneurs Star Contest" and the "Shenzhen Science and Technology Innovation Award" in 2008.

During this phase, Fapon Biotech's
technological development was reflected in two main areas:

1. The establishment and improvement of
biotechnology platforms: the polyclonal antibodies and baculovirus-insect
expression systems, mammalian expression systems, genetically engineered
recombinant antibodies and other biotechnology platforms were established. A
variety of platforms for physical and chemical analysis, such as mass
spectrometry, high-performance liquid chromatography, ultra-performance liquid
chromatography and capillary electrophoresis, were also founded to guide the
development of R&D pipelines and assess the improvement of product
performance and quality control levels.

2. The construction of a series of testing
platforms: completed the construction of immunoturbidimetry, latex-enhanced
immunoturbidimetry, fluorescence-based qPCR, CLIA, sequencing and others, which
was equipped with the reagent raw material R&D capability of most testing
methodology in the field of IVD. While improving the raw material testing and
screening capabilities, the technology of the reagent solution was accumulated.

Developed strong product lines of enzyme-linked
immunoassay, chemiluminescence, rapid test, molecular diagnostics,
biochemistry, etc., covering mainstream disease detection materials. Among
them, cTnI, malaria, CA 15-3 and many other products received high recognition
from customers for their excellent performance.

Formally certified as a national high-tech
enterprise and won the "Guangdong Science and Technology Progress
Award" and the "Shenzhen Science and Technology Innovation
Award" in 2009. Another project was approved in 2010 and 2011 as the
"National Torch Plan" in 2010 and 2011. Another product was certified
as a key new product of Guangdong province.

Guided by the value of "Future
Anticipation," insights of future development trend, industry pain points,
and more, Fapon Biotech integrated cutting-edge technologies through the mode
of "co-creation and sharing" to provide clients with
high-performance, low-cost instrument and reagent solutions, building a highly
efficient diagnostic ecosystem. Since 2017, Fapon Biotech has focused on
building an instrument platform represented by fully automatic CLIA analyzers
and a series of reagent platforms for CLIA, biochemical diagnosis and molecular
diagnosis.

During this phase, Fapon Biotech's product
development was reflected in two main areas:

1. Further diversification of raw materials:
Fapon Biotech continued to invest resources in raw material R&D projects
based on the demand of general health management and market trend, introducing
a series of new raw materials with continuous optimization, such as AMH, PG
I/II, HbA1c, cTnI, SAA, Malaria, influenza A, Dengue, NGS, etc.

2. Formation of a series of one-stop solutions:
the one-stop solutions of fully automated CLIA analyzer and reagent service, molecular
diagnosis and biochemical diagnosis were formally introduced to the market. The
business model of "Instrument + Reagent Service + Raw Material" with
personalized cooperation schemes created a new concept of one-stop solutions.

In 2018, an HIV patented product won the
Chinese Patent Silver Award; in 2020, patented Taq Polymerase won the Guangdong
Province Patent Gold Award, and Fapon Biotech became a Shenzhen Patent
Advantage Enterprise and a Guangdong Province Intellectual Property
Demonstration Enterprise. Fapon Biotech has been paying great attention to
patent application and intellectual property protection. By the end of June
2020, Fapon Biotech applied for 377 patents with 80% for invention.

Fapon Biotech has deployed instrument platforms
on NGS and POCT molecular diagnostics, with the design concept to connect
upstream developers and downstream application users in an open operation mode,
accelerating technologies innovations and product iterations, so as to meet the
urgent needs of many IVD companies and terminal users. Sequlite, a wholly-owned
subsidiary of Fapon Biotech, has completed the research and development of the
first functional prototype of a desktop mid-to-low-throughput gene sequencing
instrument, and is currently testing and optimizing the beta model in the
commercialization stage. RunPon Bioscience, a subsidiary of Fapon Biotech, has
completed the registration inspection of the first mass-produced PCR analyzer
model and is pending approval of the registration certificate.

Fapon Biotech innovatively operates the
chemiluminescence analyzers in open mode. On one hand, it helps R&D and
production enterprises of chemiluminescence reagents build complete
chemiluminescence instrument and reagent systems more efficiently, and apply to
terminal medical testing institutions, accelerating their entrance to the
chemiluminescence market. On the other hand, Fapon Biotech also share the
instrument platform to the third-party reagent developers to promote the
development of adapting reagents and transformation to clinical applications in
a more efficient way. This will help promote industrial chain collaboration,
reduce instrument development costs, as well as improve industry operational
efficiency.

In addition, Fapon Biotech has launched complete
COVID-19 testing solutions which cover various testing application scenarios.
It provides IVD enterprises with one-stop COVID-19 detection technologies and
services ranging from reagent raw materials, semi-finished products to
technical support, registration assistance, etc., empowering local diagnostics on
an industrial level. Fapon Biotech closely tracks any emergence of new variant
and continuously improves the raw materials for antigen test. At present, its
antibody raw material for antigen test has iterated to its fifth-generation.